<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Senti Biosciences Holdings, Inc. — News on 6ix</title>
<link>https://6ix.com/company/senti-biosciences-inc</link>
<description>Latest news and press releases for Senti Biosciences Holdings, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/senti-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c23578dffbe2df1193bd.webp</url>
<title>Senti Biosciences Holdings, Inc.</title>
<link>https://6ix.com/company/senti-biosciences-inc</link>
</image>
<item>
<title>Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-on-logic-gated-cell-therapies-in-educational-session-at-aacr-annual-meeting-2026</guid>
<pubDate>Mon, 13 Apr 2026 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, Co-Founder and Chief Executive Officer of Senti, will present at the AACR Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA. Dr. Lu will participate in an educational session titled “Engineered</description>
</item>
<item>
<title>Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-announces-publication-in-cell-systems-demonstrating-advanced-logic-gated-car-design-for-cell-therapies-6</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-announces-publication-in-cell-systems-demonstrating-advanced-logic-gated-car-design-for-cell-therapies-6</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-clinical-and-translational-data-on-senti-202-at-the-11th-annual-innate-killer-conference</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-clinical-and-translational-data-on-senti-202-at-the-11th-annual-innate-killer-conference</guid>
<pubDate>Mon, 23 Mar 2026 13:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California. The presentations will include data f</description>
</item>
<item>
<title>Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-at-leerink-partners-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-at-leerink-partners-2026-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 14:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will present at the Leerink Partners 2026 Global Healthcare Conference in Miami, FL on Monday, March 9, 2026, at 2:20 PM ET. A webcast replay will be av</description>
</item>
<item>
<title>Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-at-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-to-present-at-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 14:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, will highlight the Company’s Gene Circuit technology platform, pipeline progress and strategic priorities, with an emphasis on opportunities for partners</description>
</item>
<item>
<title>Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-participates-in-cell-and-gene-live-event-highlighting-cutting-edge-technologies-advancing-cell-therapy-development</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-participates-in-cell-and-gene-live-event-highlighting-cutting-edge-technologies-advancing-cell-therapy-development</guid>
<pubDate>Fri, 20 Feb 2026 13:50:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Cell & Gene Live virtual event focused on emerging and enabling technologies designed to advance the development of innovative cell therapies. The Cell & Gene Live webinar, held on February 19, 2026, conven</description>
</item>
<item>
<title>Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-completes-enrollment-phase-133500525</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-completes-enrollment-phase-133500525</guid>
<pubDate>Wed, 11 Feb 2026 13:35:00 GMT</pubDate>
<description>Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 into R/R AML pivotal study and evaluating indication expansion to include newly diagnosed AML and pediatric AML; Preparing for FDA discussions in the first half of 2026 SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may enable an expedited development and review</description>
</item>
<item>
<title>Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-selected-stage-presentation-140000804</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-selected-stage-presentation-140000804</guid>
<pubDate>Tue, 03 Feb 2026 14:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co-Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Re</description>
</item>
<item>
<title>Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-participates-virtual-investor-141500349</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-participates-virtual-investor-141500349</guid>
<pubDate>Wed, 14 Jan 2026 14:15:00 GMT</pubDate>
<description>Access the segment here SOUTH SAN FRANCISCO, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Timothy Lu, MD, PhD, CEO of Senti, discussed its recent news release announcing that the U.S. Food and Drug Administrati</description>
</item>
<item>
<title>Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-participate-panel-presentation-135500978</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-participate-panel-presentation-135500978</guid>
<pubDate>Fri, 09 Jan 2026 13:55:00 GMT</pubDate>
<description>Live panel presentation on Tuesday, January 13th at 8:00 AM PTSOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Dr. Timothy Lu, Co-Founder and CEO, will participate as a panelist alongside Jonah Comstock, Editor in Chief, pharmaphorum; Jay Hartenbach, President & COO, Diakonos</description>
</item>
<item>
<title>Senti Biosciences Announces New Employment Inducement Grants</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-announces-employment-inducement-223000838</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-biosciences-announces-employment-inducement-223000838</guid>
<pubDate>Thu, 18 Dec 2025 22:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that effective December 12, 2025 Senti Bio’s Board of Directors granted to one new employee stock options to purchase an aggregate of 13,680 shares of the Company’s common stock with a per share exercise price of $1.31 per share. Th</description>
</item>
<item>
<title>Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-receives-fda-regenerative-120000943</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-receives-fda-regenerative-120000943</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical evidence, and offers benefits of FDA working closely with Senti Bio to provide guidance and advice on generating the data needed to support approval of the product in an efficient mannerSecond FDA designation for SENTI-202 this year, after Orphan Drug Designation, is supported by clinical data showing dee</description>
</item>
<item>
<title>Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-announces-updated-senti-120000090</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-announces-updated-senti-120000090</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of all responses were MRD negative) at RP2D, 7.6 months median duration of composite Complete Remission across all patients, and a favorable safety profilePharmacodynamic data from these patients validate SENTI-202’s novel OR/NOT Logic Gate mechanism of action for selectively killing AML blasts and leu</description>
</item>
<item>
<title>Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-host-conference-call-134500235</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-host-conference-call-134500235</guid>
<pubDate>Thu, 04 Dec 2025 13:45:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it will host a conference call and webcast to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting on Tuesday, December 9, 2025 at 8:00 AM ET. The call will be hosted by Timothy Lu, MD, PhD, Chie</description>
</item>
<item>
<title>Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-reports-third-quarter-213000004</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-reports-third-quarter-213000004</guid>
<pubDate>Thu, 13 Nov 2025 21:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2025 and provided a summary of recent pipeline and corporate highlights. “Our team is laser focused on driving SENTI-202 clinical development forward. With important milestones achieved in t</description>
</item>
<item>
<title>Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-updated-clinical-140500153</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-updated-clinical-140500153</guid>
<pubDate>Mon, 03 Nov 2025 14:05:00 GMT</pubDate>
<description>Two presentations, including one oral session, build on existing data and show deep and durable clinical remission rates, combined with a strong safety profile, for SENTI-202 in treating relapsed/refractory Acute Myeloid Leukemia (AML)Pharmacodynamic data further underscore clinical proof-of-mechanism for 'OR/NOT' Logic Gate, showing selective killing of leukemic blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs)Updated clinical results co</description>
</item>
<item>
<title>Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-chardans-9th-130500697</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-chardans-9th-130500697</guid>
<pubDate>Thu, 16 Oct 2025 13:05:00 GMT</pubDate>
<description>Live webcast presentation on Tuesday, October 21st at 11:35 AM ETSOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, MD, PhD, CEO and Co-Founder of Senti Biosciences will present at Chardan’s 9th Annual Genetic Medicines Conference being held on October 21, 2025 in N</description>
</item>
<item>
<title>Senti Bio to Present at BioJapan</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-biojapan-130500575</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-biojapan-130500575</guid>
<pubDate>Mon, 06 Oct 2025 13:05:00 GMT</pubDate>
<description>In-person presentation on Thursday, October 9th at 11:30 AM JSTSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at BioJapan being held October 8-10, 2025 in Yokohama, Japan. Details of the presentation are as follows: Presenter: Timothy Lu, MD, PhD, CEO and Co</description>
</item>
<item>
<title>Senti Bio to Present at the MedInvest Biotech & Pharma Conference</title>
<link>https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-medinvest-biotech-131500494</link>
<guid isPermaLink="true">https://6ix.com/company/senti-biosciences-inc/news/senti-bio-present-medinvest-biotech-131500494</guid>
<pubDate>Thu, 18 Sep 2025 13:15:00 GMT</pubDate>
<description>Live webcast presentation on Wednesday, September 24th at 9:55 AM PTSOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, will present on Wednesday, September 24, 2025 at 9:</description>
</item>
</channel>
</rss>